linjc16/ctgov huggingface dataset:
Effects of Guiding Catheter on FFR and NHPR for the Assessment of Coronary Artery Stenoses (Disengage@Rest)

Study Overview
=================
Brief Summary
-----------------
The DISENGAGE@rest study is a prospective registry carried out at Federico II University of Naples with the aim to evaluate the influence of the guiding catheter engagement within the coronary ostium on both FFR and non-hyperaemic pressure ratios values (such as Pd/Pa and the Resting Full-cycle Ratio -RFR), as well as the corresponding clinical impact on decision-making strategies. Consecutive patients with at least one intermediate stenosis (40%-90% by visual estimation) in any of the 3 main coronary arteries will be included.

Official Title
-----------------
Effects of Guiding Catheter on Fractional Flow Reserve and Non-Hyperemic Pressure Ratios for the Assessment of Coronary Artery Stenoses - Disengage @Rest

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Fractional Flow Reserve


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years; Patients provides informed consent; Documented coronary artery disease: chronic coronary syndromes acute coronary syndromes presenting with at least one stenosis with indication for invasive functional assessment. Exclusion Criteria: Patients unable to provide informed consent; Pregnant women; Any contraindication to perform angiographic study or functional evaluation with pressure wire; Patients with aorto-ostial stenosis Target vessel diameter < 2mm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Fractional Flow Reserve|Comparison between FFR and NHPR before and after guiding catheter disengagement|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences between FFR before and after guiding catheter disengagement | Evaluate the influence of the guiding catheter engagement within the coronary ostium on FFR values. | 10 minutes | 
| 1. Differences between NHPR before and after guiding catheter disengagement | Evaluate the influence of the guiding catheter engagement within the coronary ostium on NHPR values | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fractional Flow Reserve, Resting Full-Cycle Ratio
Microbial Infection and AMR in Hospitalized Patients With Covid 19

Study Overview
=================
Brief Summary
-----------------
To detect microbial infection and AMR associated with COVID 19 infection. To correlate risk factors of COVID 19 patients with microbial infections and their effects on disease.

Detailed Description
-----------------
The most common type of infection among ICU patients was bacterial or fungal pneumonia; bloodstream and urinary tract infections were also noted. Organisms cultured from patients included pandrug-resistant Acinetobacter baumannii, Klebsiella pneumoniae carbapenemase-producing K. pneumoniae, extended-spectrum β-lactamase (ESBL)- producing K. pneumoniae, ESBL-producing Pseudomonas aeruginosa, Enterobacter cloacae, Serratia marcescens, Aspergillus fumigatus, Aspergillus flavus, Candida albicans, and Candida glabrata .

Official Title
-----------------
Microbial Infections and Antimicrobial Resistance (AMR) Patterns Associated With Hospitalized Patients With 2019 Novel Coronavirus Disease (COVID 19)

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Covid infection Exclusion Criteria: Patients without covid 19
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbial infections and antimicrobial resistance (AMR) patterns associated with hospitalized patients with 2019 novel coronavirus disease (COVID 19) | The correlation between microbial infection and COVID 19 infection and their effect on prognosis and disease outcome. | baseline |
Pulmonary Care and Research Collaborative Patient Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ILD). Medical information collected for this registry may be used to advance ILD and pulmonary research and improve patient care. This is an observational registry. Participants will not receive any investigational treatments or investigational drugs as part of their participation in this registry.

Detailed Description
-----------------
The registry will contain longitudinal medical histories of ILD patients. The creation and curation of the registry with utilize release of information services, biomedical informatics methods and human expert reviews. Among the registry's long-term goals is to utilize its data and informatics resources to study and advance ILD diagnosis and treatment. The registry will be developed with a set of capabilities to consistently, repeatedly, and economically build research-grade datasets that allow cohort development from natively unstructured and non-standard phenotypic clinical and imaging data.

Official Title
-----------------
Pulmonary Care and Research Collaborative Patient Registry

Conditions
-----------------
Interstitial Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People with a confirmed diagnosis of interstitial lung disease by a primary care physician and/or pulmonologist. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development and implementation of a database populated with de-identified longitudinal medical histories of interstitial lung disease patients. |  | Up to 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Advancing the understanding of the natural course and the treatments of interstitial lung diseases. |  | Up to 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Progressive Fibrosing Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease Associated With Systemic Sclerosis, Myositis-Associated Interstitial Lung Disease, Sarcoidosis, Hypersensitivity Pneumonitis, Pulmonary Fibrosis
Whole Breast RT on Prone Position in Korean Women

Study Overview
=================
Brief Summary
-----------------
It is well known fact that postoperative whole breast radiation therapy (RT) in left breast cancer patient can cause cardiac problem according to the exposed dose. In the several studies in other countries, it was repeatedly showed that RT on prone position can reduce cardiac exposed RT dose in left breast cancer. However, the effectiveness of prone position in RT is not studied in the Korean women have relatively small breast. The investigators planned this study to evaluate the real efficacy of prone position in Korean breast cancer treated with RT.

Official Title
-----------------
Feasibility of Prone Position in Postoperative Whole Breast Radiation Therapy in Korean Breast Cancer Patient

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Radiation: Whole breast RT on prone position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed left breast cancer 20 or older age less than 70 years old after curative resection Eastern Cooperative Oncology Group performance status 0 to 1 Informed consent to this study Consent to contraception for 6 months after RT completion Exclusion Criteria: Male breast cancer Combined distant metastasis Status of pregnant or brest feeding Previous RT history of chest or neck area Indication of supraclavicular RT Not indicated postoperative whole breast RT

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Prone position whole breast RT<br> | Radiation: Whole breast RT on prone position<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Irradiated cardiac dose |  | At simulation, expected average of 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Irradiated dose of left anterior descending artery |  | At simulation, expected average of 1 week | 
| Irradiated lung dose |  | At simulation, expected average of 1 week | 
| Clinical target volume (volume, homogeneity index, conformity index) |  | At simulation, expected average of 1 week | 
| Irradiated dose of axillary lymphatic area |  | At simulation, expected average of 1 week | 
| Skin change after RT |  | At 3 months after RT completion | 
| Breast shape after RT |  | At 6 months after RT completion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Korean, Left side
Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Study to evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens.

Official Title
-----------------
The Role of Intravenous Iron to Prevent Anemia in Women With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: ferric hydroxide saccharate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women older than 18 years Patient with operated breast cancer with indication for (NEO)adjuvant therapy They must have hemoglobin levels within the normal range (> 12g/dL), absence of renal and hepatic dysfunction as assessed by serum levels of urea, creatinine, AST, ALT. Lack of folic acid deficiency and vitamin B12 Able to provide written informed consent. Exclusion Criteria: Use of any oral supplement containing iron; Patients who have iron overload as defined by serum ferritin> 800 microg / L or transferrin saturation> 40%; Patients who are pregnant or breastfeeding; History of active infection or active bleeding except menstruation; History of HIV or hepatitis B or C - clinically important; -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: no iron supplentation<br> | |
| Experimental: iron supplement<br> | Drug: ferric hydroxide saccharate<br>* single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses<br>* Other names: NORIPURUM;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens | Anemia prevention defined by hemoglobin levels | 18 weeks |
Does Metabolic Syndrome Exist in Anorexia Nervosa?

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine whether body fat distribution changes that occur with weight gain in women recovering from anorexia nervosa are transient or persistent, and if they are associated with other features of Metabolic Syndrome.

Official Title
-----------------
Does Metabolic Syndrome Exist in Anorexia Nervosa?

Conditions
-----------------
Anorexia Nervosa, Metabolic Syndrome

Intervention / Treatment
-----------------
* Behavioral: Calorie controlled diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV diagnosis of Anorexia Nervosa (except amenorrhea) (restricting or binge eating/purging subtype) Female Age 18-40 Medically stable Participation in inpatient or daypatient treatment sufficient to restore patient to a BMI of at least 19.5kg/m² Exclusion Criteria: Additional Major Axis I disorder (including substance abuse or dependence On daily prescription medication (including oral contraceptives) History of suicide attempt or other self-injurious behavior within the previous 6 months Significant current or past medical illness,including diabetes mellitus, heart disease Indwelling metallic object (e.g., pacemaker,pump), non-removable metal jewelry or recent metallic ink tattoo

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Calorie controlled diet|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eating disorders, anorexia nervosa, body fat distribution, metabolic syndrome, visceral adipose tissue
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Study Overview
=================
Brief Summary
-----------------
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

Official Title
-----------------
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: Lasmiditan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must have completed study H8H-MC-LAHX (NCT03988088) or study H8H-MC-LAHV (NCT number to be determined) Participants must weigh at least 15 kilograms (kg) Exclusion Criteria: Participants must not be pregnant or nursing Participants must not have any acute, serious, or unstable medical condition Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lasmiditan Dose 1<br>Lasmiditan administered orally. | Drug: Lasmiditan<br>* Administered orally<br>* Other names: LY573144;|
| Experimental: Lasmiditan Dose 2<br>Lasmiditan administered orally. | Drug: Lasmiditan<br>* Administered orally<br>* Other names: LY573144;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Treatment Emergent Adverse Events (TEAEs) by Treated Migraine Attack | Percentage of TEAEs by Treated Migraine Attack | Baseline through 12 Months | 
| Percentage of Participants with Discontinuations Due to Adverse Events (AEs) | Percentage of Participants with Discontinuations Due to AEs | Baseline through 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Treated Attacks with Pain Freedom at 2 Hours | Percentage of Treated Attacks with Pain Freedom at 2 Hours | 12 Months | 
| Percentage of Treated Attacks with Pain Relief at 2 Hours | Percentage of Treated Attacks with Pain Relief at 2 Hours | 12 Months | 
| Percentage of Treated Attacks with MBS Freedom at 2 Hours | Percentage of Treated Attacks with Most Bothersome Symptom (MBS) Freedom at 2 Hours | 12 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute, long-term, open label, safety
How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement

Study Overview
=================
Brief Summary
-----------------
The OAMMM study is a mono-centrer , non interventional, prospective study, carried out in CH Valence Oral Appliance is indicated for first line moderate sleep Apnea Syndrome or severe sleep Apnea Syndrome after failure of positive airway pressure (CPAP). Clinical impact of each mm advancement of Oral Appliance is imperfectly assessed. The study aim to assess clinical and paraclinical efficacy of an oral Appliance on each mm of advancement.

Detailed Description
-----------------
Oral appliance will be delivered with a propulsion at 50% of the maximum advance and the investigator will titrate the advance according to the usual method Polygraphy and clinical effectiveness of the Oral appliance will be evaluate

Official Title
-----------------
How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolve According to Propulsion: Control With Each mm of Advancement

Conditions
-----------------
Sleep Apnea Syndromes, Sleep Apnea, Obstructive, Respiratory Tract Diseases

Intervention / Treatment
-----------------
* Behavioral: questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old Moderate sleep apnea diagnosis with clinical signs Severe sleep apnea with failure continuous positive airway pressure( CPAP) Exclusion Criteria: previous sleep apnea treatment for Moderate sleep apnea refusal to participate in research Patient under guardianship, deprived of liberty, safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| single group assignement<br> | Behavioral: questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.<br>* Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy. Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction). Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| apnea-hypopnea index | severity of sleep apnea | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epworth Sleepiness Scale score |  | 6 months | 
| pichot fatigue questionnaire |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oral appliance
Molecular Characterization of Spinal Tissue

Study Overview
=================
Brief Summary
-----------------
The researchers are trying to identify molecular mechanisms that control spine deformity and degenerative changes that can be used for therapeutic strategies.

Detailed Description
-----------------
Discarded surgical material from spinal procedures is collected. RNA analysis and other tests on the tissue is performed to determine markers of pathologic disease and to develop pharmacologic treatment strategies for pediatric spinal disorders.

Official Title
-----------------
Molecular Characterization of Spinal Tissue

Conditions
-----------------
Spinal Diseases

Intervention / Treatment
-----------------
* Other: Waste tissues are collected at the time of spinal surgery.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children and adults undergoing surgical procedures where spinal tissues are removed as a normal part of their procedure. Material from adults may be collected as a control group. Exclusion Criteria: Surgeries where spinal tissues are not being removed.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spine patients<br>Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures. | Other: Waste tissues are collected at the time of spinal surgery.<br>* This is a single visit study. Waste tissues are collected at the time of spinal surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RNA expression | Measure RNA levels in spinal tissues samples (ng/mL) | Baseline |